National and Kapodistrian University of Athens
GPER1 neuroestrogen membrane receptor: a novel, rapid-acting, promising target for psychopharmacology
Abstract
dc:descriptionMood and anxiety disorders impose a significant personal and socioeconomic burden, with women exhibiting nearly twice the lifetime prevalence compared to men. Despite the availability of several classes of antidepressant medications, current treatments for MDD remain limited, characterised by low efficacy, delayed therapeutic onset, and frequent side effects. Fluctuation of oestrogens has been linked to an increased risk of developing depression, and G protein-coupled oestrogen receptor 1 (GPER1) has emerged as a candidate rapid-acting target due to its membrane-initiated oestrogenic signalling and capacity to engage neuroplasticity-related pathways similar to ketamine. The primary objective of this PhD thesis is to elucidate the role of GPER1 in mood regulation, aiming to uncover novel therapeutic mechanisms for faster and more effective treatment of mood disorders in both sexes. A secondary objective is to determine whether GPER1 activation mimics the rapid-acting antidepressant effects of the glutamatergic agent ketamine. To address these goals, a series of experiments were designed to examine how local hippocampal GPER1 modulation, through genetic overexpression and pharmacological activation, firstly produces antidepressant and/or anxiolytic effects in female and male rats, secondly to identify the intracellular signalling cascades downstream of GPER1 in the dorsal hippocampus that are essential for its behavioural effects, focusing on the PI3K/Akt and MEK/ERK pathways, thirdly to assess whether acute systemic GPER1 activation induces rapid antidepressant- and anxiolytic-like responses in non-stressed animals, analogous to ketamine, fourthly to evaluate whether chronic systemic GPER1 activation produces sustained antidepressant effects in animals exposed to the chronic mild stress (CMS) paradigm, and lastly to characterize the molecular signalling pathways and neuroplasticity markers underlying the rapid antidepressant effects of GPER1 modulation across key mood-related brain regions. Behavioural outcomes were evaluated using the Open Field (OF), Light/Dark test (LDT), splash test (SP), novelty suppressed feeding test (NSFT) and forced swim test (FST) to assess locomotion, anxiety, motivation, and despair-related phenotypes. In separate cohorts, animals received either acute intrahippocampal infusion or systemic injection of GPER1 agonist, G1. Pharmacological inhibitors of PI3K/Akt and MEK/ERK pathways were infused intrahippocampally before G1 to dissect intracellular signalling contributions. A separate cohort was subjected to CMS to evaluate the antidepressant potential of chronic systemic G1 administration, with weekly sucrose preference testing to monitor anhedonia. Lastly, in another cohort local hippocampal GPER1 modulation, through genetic overexpression was utilised. At the molecular level, subcellular fractionation and Western blot analyses quantified downstream to GPER1 signalling markers in the hippocampus, while high-performance liquid chromatography (HPLC) with electrochemical detection was used for neurochemical profiling of monoamines, amino acids, and their metabolites, in three key regions for emotion regulation, i.e., hippocampus (HIP), prefrontal cortex (PFC), and hypothalamus (HYP). Finally, Golgi–Cox staining enabled morphometric analyses of CA1 pyramidal dendritic architecture following CMS and chronic treatment. In the first experiment, GPER1 was acutely activated locally in the dorsal hippocampus, specifically in the CA1 region, targeting the pyramidal layer. In our study, we observed that none of the treatments produced sedation or hyperactivity, or anxiolytic effects as measured in the OF and LDT tests. In the NSFT, a clear sex difference emerged, where only in females local G1 infusion significantly reduced the latency to consume the presented food in a novel anxiogenic environment, indicating a rapid anxiolytic/antidepressant-like effect. In the splash test, females receiving G1 showed a trend toward increased grooming, compatible with an antidepressant-like effect. These effects were abolished by PI3K/Akt inhibition but not by MEK/ERK inhibition, suggesting a critical role of the activated PI3K/Akt and inhibited MEK/ERK pathways in mediating GPER1’s behavioural effects in females. In the second experiment, the acute actions of GPER1 were examined after systemic administration of the selective agonist G1. Behavioural results largely reproduced the sex-specific pattern observed with local hippocampal infusion. Briefly, in the NSFT, systemic G1 significantly reduced latency to feed in females, with no effect in males. In the splash test, G1 increased grooming duration only in females, indicating improved motivational self-care after an aversive stimulus. In the FST, G1 reduced immobility selectively in females, further supporting an acute antidepressant-like action similar to ketamine.Region-specific neurochemical effects were also sex-dependent. In the PFC, G1 increased dopamine turnover indices specifically in females. In males, the reduction in cortical γ-aminobutyric acid (GABA), in the absence of parallel changes in glutamate, glutamine, or dopamine, suggests a subtle disinhibition of PFC networks. In the hippocampus, G1 did not modify catecholaminergic or serotonergic indices, indicating that acute systemic GPER1 activation does not produce large, sustained shifts in bulk monoamine content in both sexes. By contrast, hippocampal amino-acid levels were clearly altered, with G1 reducing glutamate (GLU), glutamine (GLN), and GABA, and lowering the GLU/GLN ratio and GABA levels more robustly in males. In the hypothalamus, G1 increased dopamine levels in both sexes and decreased the 5-HIAA/5-HT ratio, indicating a reduced serotonin turnover, accompanied by a non-significant trend toward higher 5-HT in females. At the molecular level, cAMP/PKA signalling showed strong sex divergence. Systemic G1 selectively reduced total PKA Cα in males, whereas females showed preserved total PKA and a trend toward increased p-PKA. These results suggest a sex-biased mode of GPCR coupling. ERK signalling showed an almost mirror-image pattern: total ERK1/2 was reduced only in females, with no significant changes in p-ERK1/2, although a small trend toward increased phosphorylation was evident. Regarding PI3K/Akt/mTOR signalling pathway, G1 increasing total Akt selectively in females, with a trend toward higher p-Akt, whereas in males showed no robust Akt changes. Lastly, mTOR levels were significantly increased in both sexes following G1. Overall, these results indicate differential coupling of GPER1 to Gα subunits based on sex, i.e., in females GPER1-Gαs coupling and males GPER1-Gαi coupling. In the third experiment, chronic mild stress produced clear signs of depressive-like behaviour in both sexes, reflected by reduced body-weight and decreased sucrose preference. G1 rescued CMS-reduced sucrose preference rapidly and robustly in males across three treatment weeks, outperforming fluoxetine, which required the full course of three weeks to achieve comparable improvement. In females, where anhedonia was less stable during early CMS exposure, G1 normalised sucrose preference in the final two treatment weeks, showing efficacy equivalent to fluoxetine. At the neuronal level, CMS induced a strong pattern of dendritic atrophy in CA1 pyramidal neurons. Apical dendrites displayed pronounced shortening under CMS in males, with corresponding trends in females, while basal dendrites showed milder effects. Chronic G1 exerted strong and widespread restorative effects on dendritic architecture. In males, G1 significantly increased apical, basal, and total dendritic length, often surpassing the magnitude observed with fluoxetine. Branch number also increased significantly under G1, reversing the CMS-induced reduction in dendritic complexity. In females, similar patterns were observed as clear trends, though not always reaching significance, consistent with the smaller magnitude of CMS-induced atrophy. Dendritic spine analysis revealed that CMS induced a significant reduction in spine density along apical dendrites and a shift in spine morphology from mushroom to thin spines in both sexes. Both G1 and fluoxetine reversed these CMS-induced spine abnormalities across sexes and dendritic compartments, restoring total spine density. In the fourth experiment, tonic enhancement of GPER1 signalling through targeted viral over-expression in dorsal CA1 pyramidal neurons showed that increased receptor abundance did not alter basal locomotor activity or exploratory drive and did not modify anxiety-like behaviour in the LDT or NSFT. On the contrary, females with GPER1 over-expression exhibited reduced immobility in the FST. Taken together, these findings demonstrate a fundamental distinction between receptor presence and receptor activation. Whereas acute pharmacological stimulation of GPER1 reliably produces anxiolytic- and antidepressant-like effects, chronic over-expression in the absence of ligand engagement does not replicate these outcomes and may only become behaviourally relevant in hormonally permissive contexts or under intense stress. These findings underscore the importance of considering sex as a biological variable in preclinical research to enhance the efficacy of future treatments. Overall, this study supports GPER1 as a novel pharmacological target whose activation could rapidly and safely alleviate depressive symptoms, improving the quality of life for millions.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Pavlidi, Pavlina
- Παυλίδη, Παυλίνα
Subjects
dc:subject × 26- Μείζων καταθλιπτική διαταραχή
- Διαφορές φύλου
- Υποδοχέας οιστρογόνων συζευγμένος με G πρωτεΐνη 1 (GPER1)
- Νευροοιστρογόνα
- Ταχέως δρώντα αντικαταθλιπτικά
- Συμπεριφορικά ζωικά μοντέλα
- Ενδοκυττάριες οδοί σηματοδότησης
- Νευροχημική ανάλυση
- Major depressive disorder (MDD
- Sex differences
- G protein-coupled oestrogen receptor 1 (GPER1)
- Neuroestrogens
- Rapid-acting antidepressants
- Behavioural animal models
- Intracellular signalling pathways
- Neurochemical analysis
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Νευροεπιστήμες
- Άλλες Ιατρικές Επιστήμες
- Ιατρική έρευνα και Πειραματική ιατρική
- Basic Medicine
- Medical and Health Sciences
- Neurosciences
- Other Medical Sciences
- Research and Experimental medicine
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/60749